Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Many patients with obsessive-compulsive disorder do not respond adequately to serotonin reuptake inhibitors. Augmentation with antipsychotic drugs can be beneficial in this regard. However, since new relevant randomized controlled trials evaluating new antipsychotics were conducted, a recalculation of the effect sizes appears necessary. We meta-analyzed all double-blind, randomized, placebo-controlled trials comparing augmentation of serotonin reuptake inhibitors with antipsychotics to placebo supplementation in treatment-resistant obsessive-compulsive disorder. The primary outcome was mean change in the Yale-Brown Obsessive–Compulsive Scale total score. Secondary outcomes were obsessions, compulsions, response rates, and attrition rates. The data collection process was conducted independently by 2 authors. Hedges’s g and risks ratios were calculated as effect sizes. In preplanned meta-regressions, subgroup analyses, and sensitivity analyses, we examined the robustness of the results and explored reasons for potential heterogeneity. Altogether, 14 double-blind, randomized, placebo-controlled trials (n=491) investigating quetiapine (N=4, n=142), risperidone (N=4, n=132), aripiprazole (N=2, n=79), olanzapine (N=2, n=70), paliperidone (N=1, n=34), and haloperidol (N=1, n=34) were incorporated. Augmentation with antipsychotics was significantly more efficacious than placebo in Yale-Brown Obsessive–Compulsive Scale total reduction (N=14, n=478; Hedges’s g=-0.64, 95% CI: -0.87 to -0.41; P=<.01). Aripiprazole (Hedges’s g=-1.35), haloperidol (Hedges’s g=-0.82), and risperidone (Hedges’s g=-0.59) significantly outperformed placebo. Antipsychotics were superior to placebo in treating obsessions, compulsions, and achieving response. There was no between-group difference concerning all-cause discontinuation. The nonsignificant meta-regressions suggest no influence of the antipsychotic dose or baseline symptom severity on the meta-analytic results. According to our findings, antipsychotic augmentation of serotonin reuptake inhibitors can be regarded as an evidence-based measure in treatment-resistant obsessive-compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Unrestricted maximum-likelihood meta-regression with mean olanzapine equivalents as continuous moderator variable. Hedges’s g refers to the effect sizes of the primary outcome (mean Yale–Brown Obsessive–Compulsive Scale [Y-BOCS] total score change). The olanzapine dose equivalents were calculated following the International Consensus Study of Antipsychotic Dosing (Gardner et al., 2010). The circle size reflects the weight a study obtained in this meta-regression. Slope=0.0002, 95% CI: -0.09 to 0.09; P=.996.](https://figures.cochat.ai/paper-figures/557e47f3e0974917a52a232803937ae6/antipsychotic-augmentation-of-serotonin-reuptake-inhibitors-in-treatment-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whilst dopaminergic medications are not first-line treatments for OCD, dopamine receptor antagonists are often used to augment first-line treatment in refractory cases (Hirschtritt et al. 2017) and the efficacy of this strategy is confirmed by meta-analyses (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
In the citing paper
“meta-analysis confirms that dopamine receptor antagonists reduce obsessive-compulsive symptoms in SSRI-refractory OCD (Dold et al. 2015; Veale et al. 2014).”
From Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder (2019) · cites this paper as Dold et al. 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“A potential publication bias was examined by funnel-plot visualization and accomplishment of Egger`s regression intercept test (2-tailed) (Egger et al., 1997).”
MethodPreferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“Haenszel random-effects model of Der-Simonian and Laired (Der-Simonian and Laird, 1986)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“…tic disorder (McDougle et al., 1994, 2000; Shapira et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Fineberg et al., 2005; Kordon et al., 2008; Simpson et al., 2013) did not alter the combined overall effect sizes in terms of statistical significance (N = 6, n = 195; Hedges’s g =…”
BackgroundA Fail-Safe N for Effect Size in Meta-Analysis
Orwin, R. G. (1983) · Journal of Educational Statistics · doi:10.2307/1164923 · Cited by 2,064 · cited 1×
“Moreover, we estimated the number of negative unpublished trials (fail-safe N value) that would be necessary to dissolve statistically significant differences (Orwin, 1983).”
BackgroundInternational Consensus Study of Antipsychotic Dosing
Gardner, D. M., Murphy, A. L., O'Donnell, H., Centorrino, F., & Baldessarini, R. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09060802 · Cited by 1,301 · cited 3×
“In unrestricted maximum-likelihood meta-regression analyses, we investigated the impact of the continuous moderators: (1) mean administered antipsychotic dose (calculated as olanzapine equivalents according to the International Consensus Study of Antipsychotic Dosing [Gardner et al., 2010]); and (2) baseline symptom s…”
MethodInfluentialKahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854 · cited 2×
“However, due to their favorable risk profile, preference should be given to the selective serotonin reuptake inhibitors (Bandelow et al., 2008; Bandelow et al., 2012; Koran and Simpson, 2013; Baldwin et al., 2014).”
BackgroundSelf-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 3×
“Our meta-analytic findings are in agreement with the guidelines for the pharmacological treatment of OCD, which consistently advise antipsychotic augmentation in SRI-resistant conditions (Bandelow, 2008; Koran and Simpson, 2013; Baldwin et al., 2014).”
BackgroundResultBloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635 · cited 1×
“Furthermore, we could confirm previous meta-analytic findings demonstrating an efficacy of the adjunctive antipsychotic pharmacotherapy (Bloch et al., 2006; Skapinakis et al., 2007).”
ResultMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570 · cited 7×
“Outcome data necessary to accomplish this meta-analysis have not been sufficiently reported (missing standard deviations) in two studies (McDougle et al., 1994; Erzegovesi et al., 2005).”
BackgroundMethodInfluentialLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“49) that was determined in a review of 33 psychopharmacological medications across all psychiatric disorders (Leucht et al., 2012).”
BackgroundSelf-citationBandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428 · cited 1×
“…behavioral therapy with exposure exercises and subsequent response prevention can be considered as well-established first-line psychotherapeutic treatment for obsessive-compulsive disorder (OCD) (Bandelow et al., 2008; Bandelow et al., 2012; Koran and Simpson, 2013; Baldwin et al., 2014).”
BackgroundSelf-citationPallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408 · cited 4×
“Since up to 40-60% of the OCD patients do not respond satisfactorily to SRI monotherapy (Pallanti and Quercioli, 2006), the question concerning the next therapeutic measures to achieve sufficient treatment”
BackgroundInfluentialSoomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342 · cited 2×
“selective serotonin reuptake inhibitors (SSRIs) and the tricyclic antidepressant clomipramine (Soomro et al., 2008; Fineberg et al., 2013; Pallanti and Hollander, 2014).”
BackgroundDenys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248 · cited 3×
“Overall attrition (outcome data reporting) was low (<10%) in 6 studies (McDougle et al., 1994, 2000; Denys et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Fineberg et al., 2005), moderate (10%-25%) in 4 (Hollander et al.”
BackgroundSimpson, H. B., Foa, E. B., Liebowitz, M. R., Huppert, J. D., Cahill, S., Maher, M. J., McLean, C. P., Bender, J., Marcus, S. M., Williams, M. T., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1932 · Cited by 248 · cited 2×
“However, in the present analysis, incorporating new relevant drugs and trials (Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013), we found the highest effect size for aripiprazole (-1.35) followed by haloperidol (-0.82), risperidone (-0.59), quetiapine (-0.50), olanzapine (-0.49),…”
BackgroundInfluentialBystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 4×
“Briefly, 8 studies described an appropriate (mainly computer-based) randomization procedure (McDougle et al., 2000; Bystritsky et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Muscatello et al., 2011; Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013) and 3 adequate concealment of allocation (By…”
BackgroundInfluentialDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211 · cited 4×
“In our previous metaanalysis on this topic (Dold et al., 2013), we concluded that risperidone can be considered as the augmenting drug of first choice and should be preferred to olanzapine and quetiapine.”
BackgroundMethodInfluentialSelf-citationHollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197 · cited 3×
“81 weeks), and the number of participants varied between 16 (Hollander et al., 2003) and 60 (Simpson et al.”
BackgroundShapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154 · cited 1×
“The blinding was insufficiently indicated in four trials (Bystritsky et al., 2004; Shapira et al., 2004; Fineberg et al., 2005; Kordon et al., 2008) for both participants/personnel (performance bias) and outcome assessment (detection bias).”
BackgroundErzegovesi, S., Guglielmo, E., Siliprandi, F., & Bellodi, L. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.04.004 · Cited by 138 · cited 9×
“…(McDougle et al., 2000; Bystritsky et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Muscatello et al., 2011; Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013) and 3 adequate concealment of allocation (Bystritsky et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005).”
BackgroundMethodInfluentialSkapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 136 · cited 1×
“The subgroup analysis investigating the minimal duration of adequate SRI treatment before randomization to the augmentation groups revealed significant differences in disfavor of the subgroup with the shortest time frame ( 8 weeks).”
BackgroundCarey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133 · cited 1×
“…(McDougle et al., 2000; Bystritsky et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005; Muscatello et al., 2011; Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013) and 3 adequate concealment of allocation (Bystritsky et al., 2004; Carey et al., 2005; Erzegovesi et al., 2005).”
Clozapine-Induced Obsessive-Compulsive Symptoms in Schizophrenia: A Critical Review
Schirmbeck, F., & Zink, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362724 · Cited by 123 · cited 2×
“The fail-safe N value estimates that 160 negative unpublished trials are necessary to dissolve statistically significant differences regarding the primary outcome.”
BackgroundMuscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122 · cited 4×
“, 2013), and high (>25%) in 4 trials (Bystritsky et al., 2004; Kordon et al., 2008; Muscatello et al., 2011; Storch et al., 2013).”
BackgroundInfluentialPharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122 · cited 1×
“In terms of the pharmacological management, there is a large body of evidence for the efficacy of serotonin reuptake inhibitors (SRIs) comprising the selective serotonin reuptake inhibitors and the tricyclic antidepressant clomipramine (Soomro et al., 2008; Fineberg et al., 2013; Pallanti and Hollander, 2014).”
BackgroundSayyah, M., Sayyah, M., Boostani, H., Ghaffari, S. M., & Hoseini, A. (2012) · Depression and Anxiety · doi:10.1002/da.21996 · Cited by 105 · cited 5×
“However, in the present analysis, incorporating new relevant drugs and trials (Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013), we found the highest effect size for aripiprazole (-1.35) followed by haloperidol (-0.82), risperidone (-0.59), quetiapine (-0.50), olanzapine (-0.49),…”
BackgroundInfluentialFineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105 · cited 5×
“The duration of the double-blind study phase ranged from 4 (McDougle et al., 1994) to 16 weeks (Fineberg et al., 2005; Muscatello et al., 2011) (mean: 8.71 ± 3.81 weeks), and the number of participants varied between 16 (Hollander et al., 2003) and 60 (Simpson et al., 2013) (mean: 35.14 ± 11.47).”
BackgroundInfluentialMaina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 101
Kordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e735 · Cited by 92 · cited 3×
“%) in 4 trials (Bystritsky et al., 2004; Kordon et al., 2008; Muscatello et al., 2011; Storch et al., 2013).”
BackgroundNational Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders
Comer, J. S., Mojtabai, R., & Olfson, M. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010087 · Cited by 86 · cited 1×
“One very frequently applied strategy in this regard contains an augmentation of SRIs with antipsychotic drugs, and recent prescription studies revealed a high and increasing prevalence of the administration of antipsychotics in OCD subjects (Comer et al., 2011; Van Ameringen et al., 2014).”
BackgroundDiniz, J. B., Shavitt, R. G., Fossaluza, V., Koran, L. M., Pereira, C. A. D. B., & Miguel, E. C. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182367aee · Cited by 84 · cited 1×
“Both other subgroups (≥8 weeks to 12 weeks and ≥12 weeks) were statistically significantly more efficacious than the <8 weeks group (for both comparisons: P = <.01) (supplementary Figure S8).”
BackgroundSchirmbeck, F., Rausch, F., Englisch, S., Eifler, S., Esslinger, C., Meyer-Lindenberg, A., & Zink, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs123 · Cited by 77 · cited 1×
“This finding underlines the need for a sufficient long duration of the initial serotonergic medication to verify SRI nonresponse before a change of the pharmacological strategy should be considered.”
BackgroundQuetiapine Augments the Effect of Citalopram in Non-Refractory Obsessive-Compulsive Disorder
Vulink, N. C. C., Denys, D. A. J. P., Fluitman, S. B. A. H. A., Meinardi, J. C. M., & Westenberg, H. G. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04269 · Cited by 75 · cited 2×
“Both other subgroups (≥8 weeks to 12 weeks and ≥12 weeks) were statistically significantly more efficacious than the <8 weeks group (for both comparisons: P = <.01) (supplementary Figure S8).”
BackgroundMethodAmisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial
Metin, Ö., Yazici, K., Tot, S., & Yazici, A. E. (2003) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.512 · Cited by 68 · cited 2×
“For example, it would be clinically meaningful to evaluate with an appropriate high-quality study design the efficacy of adjunctive amisulpride, a drug for which very promising results based on open studies and case series exist (Metin et al., 2003; Miodownik et al., 2015).”
BackgroundVan Ameringen, M., Simpson, W., Patterson, B., Dell’Osso, B., Fineberg, N., Hollander, E., Hranov, L., Hranov, G., Lochner, C., Karamustafalioglu, O., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113517955 · Cited by 65
Selvi, Y., Atli, A., Aydin, A., Besiroglu, L., Ozdemir, P., & Ozdemir, O. (2011) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1169 · Cited by 64 · cited 1×
“Both other subgroups (≥8 weeks to 12 weeks and ≥12 weeks) were statistically significantly more efficacious than the <8 weeks group (for both comparisons: P = <.01) (supplementary Figure S8).”
BackgroundDucasse, D., Boyer, L., Michel, P., Loundou, A., Macgregor, A., Micoulaud‐Franchi, J., Courtet, P., Abbar, M., Leboyer, M., & Fond, G. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3516-3 · Cited by 63
Zink, M., Schirmbeck, F., Rausch, F., Eifler, S., Elkin, H., Solojenkina, X., Englisch, S., Wagner, M., Maier, W., Lautenschlager, M., et al. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12258 · Cited by 52 · cited 1×
“This finding underlines the need for a sufficient long duration of the initial serotonergic medication to verify SRI nonresponse before a change of the pharmacological strategy should be considered.”
BackgroundSesia, T., Bizup, B., & Grace, A. A. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s146114571200154x · Cited by 49
The Medical Treatment of Obsessive-Compulsive Disorder and Anxiety
Bandelow, B. (2008) · CNS Spectrums · doi:10.1017/s1092852900026924 · Cited by 49
Storch, E. A., Goddard, A. W., Grant, J. E., De Nadai, A. S., Goodman, W. K., Mutch, P. J., Medlock, C., Odlaug, B., McDougle, C. J., & Murphy, T. K. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08278 · Cited by 45 · cited 5×
“However, in the present analysis, incorporating new relevant drugs and trials (Sayyah et al., 2012; Simpson et al., 2013; Storch et al., 2013), we found the highest effect size for aripiprazole (-1.35) followed by haloperidol (-0.82), risperidone (-0.59), quetiapine (-0.50), olanzapine (-0.49),…”
BackgroundInfluentialPallanti, S., & Hollander, E. (2014) · CNS Spectrums · doi:10.1017/s1092852913000618 · Cited by 20 · cited 2×
“In terms of the pharmacological management, there is a large body of evidence for the efficacy of serotonin reuptake inhibitors (SRIs) comprising the selective serotonin reuptake inhibitors and the tricyclic antidepressant clomipramine (Soomro et al., 2008; Fineberg et al., 2013; Pallanti and Hollander, 2014).”
BackgroundMiodownik, C., Bergman, J., Lerner, P. P., Kreinin, A., & Lerner, V. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000065 · Cited by 16
Research works printed but not linked: 2
- Borenstein, 2006, Comprehensive meta-analysis, version 2
- The Cochrane Collaboration, 2014, Review Manager (RevMan) [Computer program]. Version 5.3
Cited by
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Del Casale, A., Sorice, S., Padovano, A., Simmaco, M., Ferracuti, S., Lamis, D. A., Rapinesi, C., Sani, G., Girardi, P., Kotzalidis, G. D., et al. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180813155017 · Cited by 223
“0b013e318185e735] [PMID: 18794652] [148] Dold, M.”
BackgroundInfluentialFineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
“…there is randomized controlled trial (RCT) and meta-analytic evidence to support augmentation with an second-generation antipsychotic (Brakoulias and Stockings, 2019; Dold et al., 2015; Stein et al., 2012; Zhou et al., 2019); however, the use of these agents would be considered off-label.”
BackgroundClinical practice guidelines for Obsessive-Compulsive Disorder
Janardhan Reddy, Y., Sundar, A., Narayanaswamy, J., & Math, S. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196976 · Cited by 156
Kim, S. J., Roh, D., Jung, H. H., Chang, W. S., Kim, C.-H., & Chang, J. W. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.170188 · Cited by 121
Metadata
- Authors
- Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S.
- Affiliations
- Universitätsklinikum Tulln (AT)
- Corresponding author
- Kasper, Siegfried
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-04
- Volume
- 18
- Issue
- 9
- Pages
- pyv047
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4576518
- OpenAlex
- W4244844159
- Cited by
- 134
- References
- 49
- Citations by year
- 2026: 19 · 2025: 11 · 2024: 16 · 2023: 7 · 2022: 8 · 2021: 12 · 2020: 16 · 2019: 16 · 2018: 10 · 2017: 11 · 2016: 7 · 2015: 1
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Servier
- H. Lundbeck A/S
- Cilag
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- treatment-resistant OCD, antipsychotic augmentation, serotonin reuptake inhibitors, quetiapine, risperidone, aripiprazole, olanzapine, paliperidone, haloperidol, Yale-Brown Obsessive Compulsive Scale, obsessions and compulsions, treatment response, attrition, antipsychotic dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.